These findings advocate for a multimodal diagnostic strategy that integrates both conventional and advanced diagnostic tools to enhance detection, guide biopsy, improve staging, and optimize personalized treatment in borderline PSA level but high-volume, aggressive prostate cancer patients. The gene discussed is KLK3; the disease is prostate carcinoma.